Patents Assigned to Ikaria, Inc.
-
Patent number: 11939617Abstract: Provided herein are compositions and methods for generating polypeptides using non-natural amino acids (nnAAs) and genetic machinery, wherein the modified polypeptides, such as therapeutic polypeptides, bind to albumin, such as serum albumin. Methods of substituting a non-natural amino acid in a first polypeptide to obtain a modified polypeptide, the nnAA in some instances comprising an albumin targeting group, are disclosed, as are methods for making populations of such modified polypeptides. A therapeutic polypeptide, interleukin-1 receptor antagonist (IL-1RA) is exemplified using the disclosed methods.Type: GrantFiled: December 2, 2021Date of Patent: March 26, 2024Assignee: Ikaria Inc.Inventor: Stephen DiMagno
-
Patent number: 11214820Abstract: Provided herein are compositions and methods for generating polypeptides using non-natural amino acids (nnAAs) and genetic machinery, wherein the modified polypeptides, such as therapeutic polypeptides, bind to albumin, such as serum albumin. Methods of substituting a non-natural amino acid in a first polypeptide to obtain a modified polypeptide, the nnAA in some instances comprising an albumin targeting group, are disclosed, as are methods for making populations of such modified polypeptides. A therapeutic polypeptide, interleukin-1 receptor antagonist (IL-1RA) is exemplified using the disclosed methods.Type: GrantFiled: September 5, 2017Date of Patent: January 4, 2022Assignee: Ikaria Inc.Inventor: Stephen DiMagno
-
Publication number: 20140287066Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.Type: ApplicationFiled: June 9, 2014Publication date: September 25, 2014Applicant: IKARIA, INC.Inventors: Helen H. Usansky, Khurram Jamil
-
Patent number: 8778413Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.Type: GrantFiled: May 12, 2011Date of Patent: July 15, 2014Assignee: Ikaria, Inc.Inventors: Helen H. Usansky, Khurram Jamil
-
Patent number: 8226986Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.Type: GrantFiled: March 16, 2011Date of Patent: July 24, 2012Assignee: Ikaria, Inc.Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward A. Wintner, Csaba Szabo
-
Patent number: 8202997Abstract: A method for treating or preventing injury of a biological material exposed to hypoxic or ischemic conditions comprising contacting the biological material with an effective amount of a compound is disclosed. The compound has the following structure (I): R1—(S)n—R2 ??(I) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, and n are as defined herein. Compounds, methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: GrantFiled: October 16, 2009Date of Patent: June 19, 2012Assignee: Ikaria, Inc.Inventors: Edward A. Wintner, Fuqiang Ruan
-
Publication number: 20120042875Abstract: Methods and systems for delivering a total quantity of pharmaceutical gas to a patient. The methods and systems provide one of a low amount and high amount of pharmaceutical gas to a patient. The selection of the high amount or low amount may be determined by comparing the amount per unit of time of pharmaceutical gas delivered to the patient over the past number of breaths to the required quantity of pharmaceutical gas per unit of time. Upon completion of delivering the total quantity of pharmaceutical gas to the patient, the system can terminate, continue, activate and alarm, etc.Type: ApplicationFiled: October 28, 2011Publication date: February 23, 2012Applicant: Ikaria, Inc.Inventors: Frederick J. Montgomery, Duncan P. L. Bathe
-
Publication number: 20120042876Abstract: Methods and systems for delivering a pharmaceutical gas to a patient. The methods and systems provide a known desired quantity of the pharmaceutical gas to the patient independent of the respiratory pattern of the patient over a plurality of breaths every nth breath, where n is greater than or equal to 1. The pharmaceutical gases include CO and NO, both of which are provided as a concentration in a carrier gas. The gas control system determines the delivery of the pharmaceutical gas to the patient to result in the known desired quantity (e.g. in molecules, milligrams or other quantified units) of the pharmaceutical gas being delivered. Upon completion of that known desired quantity of pharmaceutical gas over a plurality of breaths, the system can either terminate, continue, activate and alarm, etc.Type: ApplicationFiled: November 2, 2011Publication date: February 23, 2012Applicant: Ikaria, Inc.Inventors: Frederick J. Montgomery, Duncan P.L. Bathe
-
Publication number: 20110217226Abstract: Method and apparatus of making 99.99% pure gaseous carbon monoxide comprising the steps of degassing liquid formic acid producing degassed liquid formic acid; reacting the degassed liquid formic acid or a degassed gaseous formic acid with a liquid mineral acid at an elevated temperature producing a gas phase comprising carbon monoxide gas and water vapor and a liquid phase; condensing the gas phase producing liquid water and gaseous carbon monoxide; scrubbing the carbon monoxide gas producing a gaseous 99.99% pure carbon monoxide having a purity of at least 99.99%, and, compressing the gaseous 99.99% pure carbon monoxide producing the 99.Type: ApplicationFiled: March 2, 2011Publication date: September 8, 2011Applicant: Ikaria, Inc.Inventors: Tammer Mosa, Gerard T. Taylor
-
Publication number: 20110195945Abstract: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.Type: ApplicationFiled: February 11, 2011Publication date: August 11, 2011Applicant: Ikaria, Inc.Inventors: Fuqiang Ruan, Edward A. Wintner, Thomas L. Deckwerth
-
Publication number: 20110162994Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.Type: ApplicationFiled: March 16, 2011Publication date: July 7, 2011Applicant: Ikaria, Inc.Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward Wintner, Csaba Szabo
-
Publication number: 20110165268Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.Type: ApplicationFiled: March 16, 2011Publication date: July 7, 2011Applicant: Ikaria, Inc.Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward Wintner, Csaba Szabo
-
Patent number: 7945301Abstract: The present invention relates to a method and apparatus for the administration of carbon monoxide (CO) to a patient. It allows the safe and effective use of carbon monoxide as a medicament.Type: GrantFiled: July 14, 2009Date of Patent: May 17, 2011Assignee: Ikaria, Inc.Inventors: Christian Krebs, Rainer Müllner
-
Patent number: 7923037Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.Type: GrantFiled: January 31, 2008Date of Patent: April 12, 2011Assignee: Ikaria, Inc.Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward Wintner, Csaba Szabo
-
Publication number: 20100183748Abstract: Methods for treating or preventing radiocontrast agent induced kidney injury in a mammal are disclosed, the methods comprising administering to the mammal a first effective amount of a chalcogenide composition prior to administering a radiocontrast agent to the mammal.Type: ApplicationFiled: January 20, 2010Publication date: July 22, 2010Applicant: Ikaria, Inc.Inventors: Chienmin Su, Csaba Szabo
-
Publication number: 20100143503Abstract: The present invention provides methods of reducing the cytotoxic effects of nitric oxide and sulfides comprising coadministering nitric oxide with sulfide. In addition, the present invention provides novel pharmaceutical compositions comprising both nitric oxide and sulfide. The methods and compositions of the present invention may be used in the treatment or prevention of a variety of diseases and disorders, and also in the prevention of cell or tissue damage, including that resulting from ischemi hypoxia.Type: ApplicationFiled: December 20, 2007Publication date: June 10, 2010Applicant: Ikaria, Inc.Inventors: Csaba Szabo, Kevin James Tomaselli
-
Publication number: 20100130555Abstract: A method for treating or preventing injury of a biological material exposed to hypoxic or ischemic conditions comprising contacting the biological material with an effective amount of a compound is disclosed. The compound has the following structure (I): R1—(S)n—R2 ??(I) or a stereoisomer, pharmaceutically acceptable salt or prodrug thereof, wherein R1, R2, and n are as defined herein. Compounds, methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.Type: ApplicationFiled: October 16, 2009Publication date: May 27, 2010Applicant: Ikaria, Inc.Inventors: Edward A. Wintner, Fuqiang Ruan
-
Publication number: 20080187604Abstract: The present invention provides novel stable, liquid compositions comprising chalcogenides or salts thereof. These compositions may be used for a variety of purposes, including the treatment and prevention of ischemic or hypoxic injury, as well as in the preservation of biological matter.Type: ApplicationFiled: October 5, 2007Publication date: August 7, 2008Applicant: IKARIA, INC.Inventors: Kevin J. Tomaselli, Paul A. Hill, Thomas L. Deckwerth, Edward Wintner, Csaba Szabo
-
Publication number: 20070265223Abstract: The present invention provides methods, compositions, and articles of manufacture comprising adenosine, an adenosine derivative or analog, an adenosine receptor agonist, a chemical entity that is taken up by a nucleoside transporter, or a chemical entity that binds to and/or modulates a nucleoside transporter, which protect biological material from cellular or tissue damage resulting from ischemia or hypoxia, including ischemia and hypoxia due to injury, disease, or hemorrhaging. These methods, compositions, and articles of manufacture also enhance the survivability of biological material subjected to ischemia due to injury, disease, or hemorrhage.Type: ApplicationFiled: March 12, 2007Publication date: November 15, 2007Applicant: IKARIA, INC.Inventors: Kevin Tomaselli, Thomas Deckwerth